LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review

NDA FilingDersimelagonPositive

AI Analysis

Summary

LEO Pharma announced FDA acceptance of its NDA for Dersimelagon with Priority Review status granted. The Priority Review designation accelerates the FDA's evaluation timeline for this dermatological treatment.

Outcome Details

FDA accepted NDA for filing and granted Priority Review

Importance:7/10

Sentiment:

0.70

NDA_AcceptancePriority_ReviewFDADermatology

Related Companies

$MDCE $GBCMD

Read the original article

Published by Drugs.com New Drug Applications on September 18, 2026 11:09 PM

Read Original